ReviewWorld journal of gastroenterology2019
Colorectal peritoneal metastases: Optimal management review.
Review in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.World journal of surgical oncology · 2022Pooled it
- Epigenomic profiling links IGF2 overexpression to anthracycline resistance in colorectal cancer organoids.JCI insight · 2026Article
- Impact ofCancers · 2026Article
- Clinical spotlight review: best practices for the management of colorectal cancer in the emergency and acute care setting.Surgical endoscopy · 2026Review
- A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC.Annals of surgical oncology · 2026Article
- Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases.Annals of surgical oncology · 2026Review
- Article
- Article
- Management of peritoneal metastases from colorectal cancer and small bowel adenocarcinoma in patients with inflammatory bowel disease.World journal of gastrointestinal oncology · 2025Review
- Long-term survival of a patient with colorectal cancer with peritoneal carcinomatosis and low completeness of cytoreduction score: A case report.World journal of gastrointestinal oncology · 2025Article
- Tumor Deposits in Non-Metastatic Colorectal Cancer as a Risk Factor of Peritoneal Metastasis.International journal of medical sciences · 2025Article
- Article
- Factors Affecting the Prognosis after Primary Tumor Resection for Patients with Metastatic Colorectal Cancer with Synchronous Peritoneal Metastasis: A Multi-center, Prospective, Observational Study.Journal of the anus, rectum and colon · 2025Article
- Prognostic Value of Immune Scoring System for Colorectal Cancer Patients with Peritoneal Metastasis.Medicina (Kaunas, Lithuania) · 2024Article
- The role of multimodality imaging in the selection and management of patients treated with cytoreductive surgery and HIPEC.Abdominal radiology (New York) · 2024Review
- Preoperative chemotherapy response and survival in patients with colorectal cancer peritoneal metastases.Journal of surgical oncology · 2024Article
- Cytoreductive surgery without intra-peritoneal chemotherapy for metachronous colorectal peritoneal metastases.World journal of surgical oncology · 2024Article
- Neoadjuvant chemotherapy does not improve survival for patients with high volume colorectal peritoneal metastases undergoing cytoreductive surgery.World journal of surgical oncology · 2024Article
- Normal CEA Levels After Neoadjuvant Chemotherapy and Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion Predict Improved Survival from Colorectal Peritoneal Metastases.Annals of surgical oncology · 2024Article
- Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery.Annals of surgical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The peritoneum is a common site of dissemination for colorrectal cancer, with a poorer prognosis than other sites of metastases. In the last two decades, it has been considered as a locoregional disease progression and treated as such with curative intention treatments. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the actual reference treatment for these patients as better survival results have been reached as compared to systemic chemotherapy alone, but its therapeutic efficacy is still under debate. Actual guidelines recommend that the management of colorectal cancer with peritoneal metastases should be led by a multidisciplinary team carried out in experienced centers and consider CRS + HIPEC for selected patients. Accumulative evidence in the last three years suggests that this is a curative treatment that may improve patients disease-free survival, decrease the risk of recurrence, and does not increase the risk of treatment-related mortality. In this review we aim to gather the latest results from referral centers and opinions from experts about the effectiveness and feasibility of CRS + HIPEC for treating peritoneal disease from colorectal malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.